Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma by Han, Mingzhi et al.
Article
Therapeutic implications of altered cholesterol
homeostasis mediated by loss of CYP46A1 in
human glioblastoma
Mingzhi Han1,2,†, Shuai Wang1,† , Ning Yang1, Xu Wang1, Wenbo Zhao1, Halala Sdik Saed2,
Thomas Daubon3,4, Bin Huang1, Anjing Chen1,5, Gang Li1, Hrvoje Miletic2,6, Frits Thorsen2,7 ,
Rolf Bjerkvig2,8,*,‡ , Xingang Li1,‡,** & Jian Wang1,2,‡,***
Abstract
Dysregulated cholesterol metabolism is a hallmark of many
cancers, including glioblastoma (GBM), but its role in disease
progression is not well understood. Here, we identified cholesterol
24-hydroxylase (CYP46A1), a brain-specific enzyme responsible for
the elimination of cholesterol through the conversion of choles-
terol into 24(S)-hydroxycholesterol (24OHC), as one of the most
dramatically dysregulated cholesterol metabolism genes in GBM.
CYP46A1 was significantly decreased in GBM samples compared
with normal brain tissue. A reduction in CYP46A1 expression was
associated with increasing tumour grade and poor prognosis in
human gliomas. Ectopic expression of CYP46A1 suppressed cell
proliferation and in vivo tumour growth by increasing 24OHC
levels. RNA-seq revealed that treatment of GBM cells with 24OHC
suppressed tumour growth through regulation of LXR and SREBP
signalling. Efavirenz, an activator of CYP46A1 that is known to
penetrate the blood–brain barrier, inhibited GBM growth in vivo.
Our findings demonstrate that CYP46A1 is a critical regulator of
cellular cholesterol in GBM and that the CYP46A1/24OHC axis is a
potential therapeutic target.
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Introduction
Glioblastoma (GBM) is the most common primary malignant brain
tumour in adults (Fack et al, 2017; Lhomond et al, 2018). Despite
aggressive therapy, including maximal surgical resection followed
by radiotherapy and temozolomide treatment, the median patient
survival is 14.6 months from initial diagnosis (Stupp et al, 2005).
New treatment strategies are therefore urgently needed.
Emerging evidence has linked disrupted cholesterol homeostasis
to cancer development including GBM (Bovenga et al, 2015; Kuzu
et al, 2016; Cheng et al, 2018). However, epidemiological data
remain contradictory regarding the relationship between cancer risk
and serum cholesterol levels, suggesting that circulating cholesterol
levels alone have marginal effects on cancer development (Silvente-
Poirot et al, 2018). Oxysterols are oxygenated derivatives of choles-
terol that participate in the regulation of cholesterol metabolism.
They are derived from the diet or generated through endogenous
cholesterol metabolism in tissues. Oxysterols include 24-hydroxy-
cholesterol (24OHC), 25-hydroxycholesterol (25OHC), 27-hydroxy-
cholesterol (27OHC) and ring oxysterols (Janowski et al, 1996;
Berrodin et al, 2010) that are known to, in addition to cholesterol
metabolism regulation, modulate signalling pathways such as
Hedgehog, Wnt and MAPK (Kloudova et al, 2017). In neurodegener-
ative disease and cancer, oxysterols interact with specific proteins
and transcription factors, such as the liver X receptors (LXR) and
oxysterol-binding protein and insulin-induced gene 1 (INSIG1)
(Kloudova et al, 2017). Recently, it has been shown that 27OHC can
inhibit prostate cancer growth through depletion of intracellular
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cholesterol levels (Alfaqih et al, 2017). Yet, others have shown, in
breast cancer cells, that 27OHC induces an epithelial-to-mesench-
ymal transition (EMT) leading to increased tumour growth (Torres
et al, 2011; Wu et al, 2013). It has also been shown in a subtype of
early-stage hepatocellular carcinoma that disrupted cholesterol
homeostasis is associated with poor prognosis (Jiang et al, 2019). In
GBM, the notion that excessive accumulation of cholesterol can fuel
the growth of tumour cells has been supported by the following
evidence. First, de novo cholesterol synthesis is suppressed in GBM
cells compared with normal human astrocytes leading to exogenous
cholesterol uptake through up-regulation of the low-density lipopro-
tein receptor (LDLR) (Villa et al, 2016). Second, loss of endogenous
oxysterols in GBM leads to decreased cholesterol efflux (Villa et al,
2016). At present, the mechanisms causing dysregulation of choles-
terol homeostasis in GBM are not clear, especially with regard to
oxysterol loss.
In mammals, cholesterol homeostasis is tightly regulated by a
complex protein network centred around two groups of transcrip-
tion factors, sterol-regulatory binding proteins (SREBPs) and liver X
receptors (LXRs), that are involved in cholesterol import, export,
synthesis, metabolism and esterification (Ikonen, 2008). SREBPs
mainly promote the transcription of genes, such as HMGCR and
LDLR, that are involved in cholesterol synthesis and uptake when
intracellular cholesterol levels decrease. LXRs respond to excessive
intracellular cholesterol by inducing the expression of genes, such
as ABCA1 and ABCG1, that are responsible for cholesterol efflux
and LDLR degradation through induction of the E3 ubiquitin ligase
IDOL (Zelcer et al, 2009). Targeting these pathways has been shown
to be an effective strategy for inhibiting growth in GBM animal
models (An & Weiss, 2016).
Cancer cells have clearly developed mechanisms for an accumu-
lation of excessive intracellular cholesterol in order to support their
growth. Cholesterol metabolism might therefore represent a poten-
tial therapeutic target. However, the key factors contributing to the
accumulation of cholesterol in GBMs remain unclear. Here, we used
large-scale in silico analyses of whole-transcriptome databases to
identify dysregulated genes in GBMs involved in cholesterol home-
ostasis. One of the most dramatically down-regulated genes was
cholesterol 24-hydroxylase (CYP46A1), a brain-specific enzyme
responsible for the elimination of cholesterol through conversion of
cholesterol into 24(S)-hydroxycholesterol (24OHC) (Moutinho et al,
2016). CYP46A1 expression emerged as a prognostic marker in GBM
patients, and in functional studies, overexpression or pharmacologi-
cal activation of the CYP46A1/24OHC axis suppressed GBM cell
growth in vitro and in vivo. Our results show that changes in
CYP46A1 are critical for the dysregulation of cholesterol homeosta-
sis in GBM and that targeting CYP46A1/24OHC may provide a new
opportunity for GBM therapy.
Results
Cholesterol level promotes GBM cell growth
First, we determined the difference in cholesterol regulation
between GBM and normal brain. Gene set enrichment analysis
(GSEA) based on the Rembrandt data revealed that GBM (n = 217)
and normal brain tissues (n = 28) displayed a distinct enrichment
of cholesterol metabolic processes compared with normal brain
(Appendix Fig S1A). Cholesterol synthesis, however, was positively
associated with normal brain (adjusted P < 0.05, respectively;
Appendix Fig S1A), which is consistent with previous reports indi-
cating that GBM cells mainly depend on exogenous cholesterol
synthesized by normal human astrocytes for growth (Villa et al,
2016). To confirm that GBM cells depend on exogenous choles-
terol, two GBM cell lines (LN229 and U251) and GSCs from a
primary GBM (GBM#P3) were cultured in media with FBS or in
lipoprotein-deficient serum (LPDS). Growth curves generated
revealed a significantly slower growth of GBM cells in LPDS after
5 days (P < 0.01). However, the addition of 5 lg/ml LDL (the
lipoprotein with the highest cholesterol content) to the LPDS
medium rescued GBM cell growth compared with LPDS medium
(Appendix Fig S1B–D). These data confirm the importance of
exogenous cholesterol for GBM cell growth as reported previously
(Guo et al, 2011; Geng et al, 2016).
CYP46A1 is a tumour suppressor candidate in GBM
To identify the most dysregulated cholesterol-related genes in GBM,
we performed bioinformatic analysis on publicly available genomic
datasets. First, we derived a gene signature of 176 genes involved in
cholesterol biology based on Gene Ontologies (Alfaqih et al, 2017).
Through differential analysis using the Rembrandt dataset, we
uncovered a total of 13 differentially expressed genes between GBM
(n = 217) and normal brain tissue (n = 28) (Fig 1A and B). The
brain-specific cholesterol regulator, CYP46A1, emerged as the most
differentially expressed gene with decreased expression in GBM
(log2 fold change = 2.335, adjusted P = 5.85E-25). Differential anal-
ysis based on the Chinese Glioma Genome Atlas (CGGA)
dataset also revealed CYP46A1 as one of the most dysregulated tran-
scripts (log2 fold change = 1.966, adjusted P = 4.63E-09) between
GBM (n = 128) and normal brain (n = 5; Fig EV1A–C). Univariate
Cox regression analysis in GBM patients was also used to screen the
cholesterol-related genes based on prognostic values. After ranking
by P-value, CYP46A1 emerged among the top 3 genes (APOBR,
CELA3A and CYP46A1) associated with GBM prognosis (Fig EV1D).
By analysing the Cancer Genome Atlas (TCGA) pan-cancer data
including 31 different cancer types, the expression of CYP46A1 was
found to be significantly increased in normal brain compared with
GBM and LGG (Appendix Fig S2A). Loss of CYP46A1 in GBM was
further confirmed by analysing several public glioma datasets (over
1,500 samples were enrolled; P < 0.01, respectively; Appendix Fig
S2B).
The intra-tumoral expression pattern of CYP46A1 in GBMs was
further determined using the IVY GBM RNA-seq data (http://gliobla
stoma.alleninstitute.org/). CYP46A1 was highly expressed at the
leading edge (which is mainly comprised of normal brain cells)
compared with other tumour regions (Appendix Fig S2C). Single-cell
RNA-seq data (Darmanis et al, 2017) further demonstrated that
CYP46A1 is mainly expressed in neurons, astrocytes and oligoden-
drocyte precursor cells (OPCs) and to a lesser extent in tumour cells
(Appendix Fig S2D). CYP46A1 protein levels were also examined in
different cell lines (Appendix Fig S2E). Normal human astrocytes
(NHAs) displayed abundant CYP46A1 protein levels, while GBM
cells (GBM#P3, GBM#05, GBM#BG7, LN229, U251 and LN18)
showed much lower expression.
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To confirm that CYP46A1 expression is reduced in GBMs at the
protein level, we performed IHC staining for CYP46A1 on an inde-
pendent cohort of glioma (n = 58) and normal brain tissue samples
(n = 6). CYP46A1 expression was found to be cytoplasmic. Expres-
sion was also consistently high in normal brain tissue (5/6; 88.3%)
compared with LGG (14/24; 58.3%) and GBM (6/34; 17.6%), and
decreased with increasing glioma grade (Fig 1C and D). IHC staining
in one specific GBM sample demonstrated that CYP46A1 was posi-
tively expressed in adjacent brain tissue while absent in GBM
(Fig 1E). IHC data from the Human Protein Atlas (n = 17) corrobo-
rated these results, confirming high expression of CYP46A1 in
normal brain (Fig EV2A), which decreased with increasing tumour
grade (Fig EV2B and C).
We subsequently assessed CYP46A1 levels based on the 2016
WHO classification of gliomas, using the TCGA data. CYP46A1 was
higher in three LGG subtypes (LGG-Oligo, LGG-Astro and LGG-
IDHwt) and lower in GBM-IDHmt and GBM-IDHwt (Fig 1F).
Although there is a general down-regulation of CYP46A1 in GBM
compared with normal brain, higher expression of CYP46A1 was
also observed in the Neural GBM molecular subtype (Fig 1G), which
is associated with a more favourable prognosis, relative to the other
subtypes based on the TCGA Verhaak-2010 molecular classification
of GBM (Noushmehr et al, 2010).
To address why CYP46A1 is decreased in GBMs, we examined its
promoter/enhancer regions using the combined chromatin immuno-
precipitation sequencing (ChIP-seq) data from GEO and ENCODE
databases. Here, H3K27ac peaks (marker of active promoters) within
the promoter region of CYP46A1 were lower in GBMs compared with
normal brain tissue (Appendix Fig S3A). We also examined the
active enhancer landscape of CYP46A1 across three matched pairs of
GSCs and differentiated glioma cells (DGCs). CYP46A1 enhancers
and mRNA levels tended to decrease in GSC versus DGC, as
measured by ChIP-seq (H3K27ac and H3K4me3 peak levels) and
mRNA data (Appendix Fig S3A–C). These results were also validated
through ChIP-qPCR and Western blot analysis (Appendix Fig S3D
and E). Taken together, abnormal histone modifications may
partially explain reduced CYP46A1 expression in GBM.
Decreased CYP46A1 levels correlate with worse survival in
glioma patients
To determine the clinical significance of CYP46A1, Kaplan–Meier
analysis was performed using the CGGA dataset. GBM patients with
high CYP46A1 mRNA levels (based on the median value) exhibited
significantly better overall survival (OS) as well as progression-free
survival (PFS) (Fig 1H and I). CYP46A1 was also a prognostic indi-
cator in LGG patients (Fig 1H and I). The prognostic value of
CYP46A1 was further validated in TCGA, Rembrandt and Phillips
datasets (Appendix Fig S4A–C). CYP46A1 was also validated as an
independent prognostic indicator using univariate and multivariate
Cox regression analysis of OS (HR = 0.390, 95% CI = 0.262 to
0.581, P < 0.001; Appendix Table S1) in CGGA patients and showed
a prognostic trend in multivariate analysis of TCGA patients. Collec-
tively, these results emphasize the prognostic relevance of CYP46A1
in GBM.
Expression of CYP46A1 attenuates GBM growth
Next, we examined the role of CYP46A1 in GBM growth in vitro.
Lentivirus was used to over-express CYP46A1 in LN229, LN18 and
GBM#P3, as validated by qRT–PCR (P < 0.001; Fig 2A) or Western
blot (Fig 2B and Appendix Fig S5A). Cell growth was significantly
inhibited in lenti-CYP46A1 compared with lenti-Ctrl cells (P < 0.01;
Fig 2C). Ectopic expression of CYP46A1 also attenuated colony
formation (P < 0.05; Fig 2D). Furthermore, increased expression of
CYP46A1 in GSCs (GBM#P3) inhibited tumorsphere formation, a
critical glioma stem-like property (P < 0.05; Appendix Fig S5B
and C).
LN229 and GBM#P3-lenti-CYP46A1 or GBM#P3-lenti-control cells
were injected intracranially into mice to evaluate tumour growth
in vivo. For both cell types, CYP46A1 overexpression inhibited
tumour growth, as observed in haematoxylin and eosin (HE) stain-
ing (Fig 2E), and prolonged overall survival in mice (P < 0.05;
Fig 2F). Overexpression of CYP46A1 also led to reduced levels of
the proliferation marker PCNA but increased expression of the apop-
totic marker cleaved caspase-3 (Fig 2G, Appendix Fig S5D and E).
These data confirm a tumour-suppressive role for CYP46A1 in
human GBM.
24OHC inhibits GBM growth and GSC maintenance
The CYP46A1 gene encodes a cytochrome P450 oxidase, sterol 24-
hydroxylase, the main function of which is to convert cholesterol
into 24OHC (Fig 3A). We therefore characterized metabolic changes
in 24OHC in human GBM. 24OHC levels were decreased in primary
GBMs (n = 3) compared with normal brain tissue samples
◀ Figure 1. Expression of CYP46A1, a gene involved in brain cholesterol homeostasis, is lost in GBM and associated with increasing tumour grade.A Heatmap of the differentially expressed cholesterol-related genes between normal brain tissues (n = 28) and glioblastomas (n = 217) from the Rembrandt dataset.
Gene expression values are z-transformed and coloured red for high expression and blue for low expression, as indicated in the scale bar.
B Volcano plot showing the fold change (log2) in cholesterol-related gene levels based on GBM versus normal brain tissue. Data were obtained from the Rembrandt
dataset.
C Representative images of IHC staining for CYP46A1 protein in normal brain and different pathological grades of gliomas (n = 64). Scale bar = 30 lm.
D Quantification of CYP46A1 IHC staining in normal brain (n = 6) and different pathological grades of gliomas (n = 58).
E Representative images of CYP46A1 IHC staining in GBM and adjacent brain tissues from one specific case. Scale bar = 30 lm.
F CYP46A1 expression levels in tumours from the TCGA dataset using 2016 WHO classification. Data are shown as the mean  the standard error of the mean (SEM;
n = 667). ***P < 0.0001. Statistical significance was determined by one-way ANOVA.
G CYP46A1 expression levels in different molecular subtypes from the Rembrandt GBM dataset. Shown are means and SEM (n = 245). ***P < 0.0001. Statistical
significance was determined by one-way ANOVA.
H–I Kaplan–Meier analysis for patient OS and PFS based on high versus low expression of CYP46A1 in LGG and GBM. Data were obtained from the CGGA dataset.
P-values were obtained from the log-rank test.
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(P < 0.05; Appendix Fig S6A). These results were consistent with
decreased CYP46A1 expression in GBM. Ectopic expression of
CYP46A1 in GBM cells in vitro, however, led to a dramatic increase
in 24OHC concentration in culture media (Fig 3B) as well as in GBM
cell pellets (P < 0.01; Appendix Fig S6B). Exogenous 24OHC
inhibited LN229 growth in a dose- and time-dependent manner
(Appendix Fig S6C and D). IC50s for 24OHC were 28.86 lM in
LN229 and 33.81 lM in GBM#P3 cells (Fig 3C).
To identify potential mechanisms for 24OHC inhibition of GBM






Figure 2. Restoration of CYP46A1 attenuates the growth of GBM cells in vitro and in intracranial GBM xenografts.
A qRT–PCR analysis of CYP46A1 mRNA levels in LN229 and GBM#P3 cells transfected with lentivirus expressing CYP46A1 (lenti-CYP46A1) or control sequence (lenti-
Ctrl). GAPDH was used as an internal control. Shown are means and SEM (n = 3). LN229: ***P < 0.0001; GBM#P3: ***P < 0.0001. Statistical significance was
determined by two-sided Student’s t-test.
B Western blot analysis to confirm CYP46A1 overexpression in GBM cells.
C Growth curves for GBM cells in vitro infected with lenti-Ctrl or lenti-CYP46A1 derived from trypan blue staining. Shown are means and SEM (n = 3). LN229:
**P = 0.003; GBM#P3: **P = 0.002. Statistical significance was determined by two-sided Student’s t-test.
D Colony-forming assay for GBM cells infected with lenti-Ctrl or lenti-CYP46A1. Shown are means and SEM (n = 3). LN229: *P = 0.013; LN18: *P = 0.012. Statistical
significance was determined by two-sided Student’s t-test.
E Representative H&E staining of orthotopic tumours derived from GBM cells infected with lenti-Ctrl or lenti-CYP46A1. Scale bar = 2 mm.
F Kaplan–Meier survival curve of tumour-bearing mice injected with GBM cells infected with lenti-Ctrl or lenti-CYP46A1 (n = 5 per group). A log-rank test was used to
assess statistical significance.
G IHC for CYP46A1, PCNA and cleaved caspase-3 protein levels in the intracranial tumours. Scale bar = 100 lm.
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using flow cytometry (analysis of Annexin V-FITC and PI staining).
Treatment of LN229 and GBM#P3 with 24OHC increased apoptosis
in a dose-dependent manner (Fig 3D and E). 24OHC also elevated
caspase-3/7 activity in LN229 (Appendix Fig S6E and F) and dramat-
ically inhibited colony formation in LN229 and LN18 compared with
controls (P < 0.001, Fig 3F). Furthermore, Western blot analysis
showed an increase in cleaved PARP and cleaved caspase-3, and a
decrease in PCNA in a time-dependent manner (Fig 3G and
Appendix Fig S6G). Cell cycle analysis based on PI staining indi-
cated only a slight increase in G2/M phase cells after 24OHC treat-
ment (Appendix Fig S6H). Finally, treatment of GSCs, GBM#P3,
GBM#BG7 and GBM#BG5, with 24OHC, led to a reduced tumor-
sphere formation (Fig 3H and I). In contrast, 24OHC was less toxic
to normal human astrocytes (NHAs) and rat brain organoids
(Fig EV3A–C). In summary, these data show that 24OHC specifically
inhibits GBM growth.
24OHC suppresses the growth of GBM cells by reducing
cholesterol accumulation
It has been shown that neurons and astrocytes both produce oxys-
terols, including 24OHC, as a result of brain cholesterol metabolism.
These molecules act as endogenous ligands for the liver X receptors
(LXRs) to decrease excess cellular cholesterol levels (Repa et al,
2000; Venkateswaran et al, 2000; Zelcer et al, 2009; Chen et al,
2013). In GBM cells in vitro, 24OHC treatment resulted in a signifi-
cant decrease in total intracellular cholesterol levels (P < 0.01,
Fig 4A) and filipin staining which reflects free cholesterol levels
(Fig 4B). These results therefore show that 24OHC inhibits GBM cell
growth by depleting intracellular cholesterol. To further validate
24OHC induced growth inhibition, rescue experiments with choles-
terol were performed in LN229 cells. The addition of exogenous
cholesterol significantly increased the growth of 24OHC treated cells
(P < 0.0001; Fig 4C). Cholesterol also attenuated apoptosis caused
by 24OHC in both LN229 and GBM#P3 (Fig 4D) and decreased
cleaved PARP (Fig 4E). Cholesterol also compensated for the reduc-
tion in GSC sphere formation caused by 24OHC in both GBM#P3
and GBM#BG7 cells (P < 0.05; Fig 4F). Finally, exposure to methyl-
b-cyclodextrin (MbCD), which depletes cellular cholesterol, also
inhibited GBM cell survival (P < 0.001 at 10 mM; Fig 4G). In
conclusion, these results demonstrated that 24OHC suppresses GBM
growth by depleting cellular cholesterol.
24OHC inhibits GBM growth through regulation of LXR and
SREBP1 activity
To determine the mechanisms underlying 24OHC inhibition of GBM
growth, we performed RNA sequencing (RNA-seq) of GBM#P3 cells
treated with or without 24OHC (heatmap Fig 5A). GO analysis indi-
cated that differentially expressed genes were closely related to
biological processes involved in negative regulation of lipid storage
and positive regulation of cholesterol efflux, cholesterol homeostasis
and cell apoptosis. In addition, inflammatory signalling pathways
including IL-10 and NF-jB pathways were regulated by 24OHC
(Fig 5B). KEGG pathway analysis also indicated that these genes
were strongly associated with the LDLR pathway, the FXR (farne-
soid X receptor) and LXR regulation of cholesterol metabolism
(Fig 5C). Moreover, GSEA showed that 24OHC was associated with
positive regulation of cholesterol efflux, but negatively associated
with gene signatures linked to cholesterol homeostasis, SREBP
targets and stem cell proliferation (Fig 5D). A volcano plot of the
RNA-seq results revealed significant changes in several target genes
of two cholesterol homeostasis transcription factors, LXR and
SREBPs. Interestingly, GSC stemness markers, including SOX2 and
SOX4, decreased after exposure to 24OHC (Fig 5E), which was
consistent with a decreased tumorsphere formation ability. RNA-seq
results for these genes were further confirmed by qRT–PCR (Fig 5F)
and immunofluorescence staining of SOX2 in GBM#P3 tumor-
spheres treated with 24OHC (Appendix Fig S7A).
24OHC is an endogenous LXR agonist (Chen et al, 2013). We
found that 24OHC triggered GBM cell death in the presence of LXR-
623 (P < 0.05; Fig 5G), which is an effective synthetic LXR agonist
(Villa et al, 2016). These results indicate that 24OHC might kill
GBM cells not only through activation of LXR, but also through
other mechanisms. Based on the RNA-seq data, 24OHC was also
found to suppress SREBP signalling (Fig 5D and E). Analysis of the
genomic datasets consistently showed that SREBP1 was the predom-
inant SREBP isotype expressed in GBMs predicting poor overall
survival (Appendix Fig S7B). This is consistent with prior reports
showing that SREBP1, but not SREBP2, contributes to GBM progres-
sion and tumorigenesis (Geng et al, 2016). We thus reasoned that
24OHC influenced SREBP1 transcriptional activity in GBM. On
Western blots, proteins levels were correspondingly altered; 24OHC
caused a decrease in protein levels of nuclear SREBP1 (N-SREBP1),
precursor SREBP1 (P-SREBP1) and LDLR as well as an induction of
▸Figure 3. CYP46A1 inhibits the growth of GBM cells through the production of 24OHC.A Schematic model of cholesterol conversion into 24OHC catalysed by CYP46A1.
B 24OHC levels in spent media from LN229 (left) and GBM#P3 (right) cells transduced with lenti-Ctrl or lenti-CYP46A1 measured using targeted LC-MS/MS. Data are
shown as the mean  SEM (n = 3). Statistical significance was determined by two-sided Student’s t-test (see Materials and Methods).
C IC50 curves for 24OHC in LN229 and GBM#P3 cells using the CCK-8 assay.
D, E Flow cytometry to detect Annexin V-FITC and PI staining to determine the percentage of LN229 and GBM#P3 cells undergoing apoptosis after exposure to
0–20 lM 24OHC for 72 h. Data are shown as the mean  SEM (n = 3). LN229: ***P = 0.0005, ***P < 0.0001, ***P < 0.0001; GBM#P3: *P = 0.035, ***P = 0.0006,
***P < 0.0001. Statistical significance was determined by one-way ANOVA.
F Colony-forming ability of GBM cell lines treated with 24OHC (0–20 lM) for 14 days. Data are shown as the mean  SEM (n = 3). ***P < 0.0001. Statistical
significance was determined by one-way ANOVA.
G Western blot analysis of the apoptosis marker c-PARP, c-caspase-3 and PCNA in lysates (20 lg) from GBM cells treated with 24OHC (0–20 lM) for 72 h.
H–I Tumorsphere formation assays for GSCs treated with different concentrations of 24OHC (0–20 lM). Scale bar = 100 lm. Graphic representation of the
quantification of tumorsphere formation. Data are shown as the mean  SEM (n = 3). GBM#P3: *P = 0.0192, ***P = 0.0006, ***P = 0.0002; GBM#BG7:
**P = 0.0017, ***P < 0.0001, ***P < 0.0001; GBM#BG5: **P = 0.0027, ***P = 0.0001, ***P < 0.0001. Statistical significance was determined by one-way ANOVA.
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ABCA1 (Fig 5H and Appendix Fig S7C). More importantly, overex-
pression of SREBP1 partially rescued 24OHC-induced growth inhibi-
tion of LN229 cells (P < 0.01, Fig 5I). Furthermore, a specific SREBP
antagonist, fatostatin, suppressed the growth of LN229 and LN18
cells in vitro (P < 0.001, Fig 5J) and GBM#P3 tumour growth in vivo






Figure 4. 24OHC suppresses the growth of GBM cells by reducing cholesterol content.
A Intracellular levels of cholesterol in GBM cells treated with 20 lM of 24OHC or DMSO for 72 h quantified using the InvitrogenTM AmplexTM Red Cholesterol Assay Kit
and normalized to total protein. Shown are means and SEM (n = 3). LN229: **P = 0.002; GBM#P3: **P = 0.011. Statistical significance was determined by two-sided
Student’s t-test.
B Representative images of filipin staining in GBM cells treated with different concentrations of 24OHC (0–20 lM) for 72 h. Scale bar = 30 lm.
C Growth curves for LN229 cells treated with DMSO, 0.5 lg/ml cholesterol or 10 lM 24OHC in the presence or absence of 0.5 lg/ml cholesterol using trypan blue
staining. Data are shown as the mean  SEM (n = 3). ***P < 0.0001. Statistical significance was determined by one-way ANOVA.
D Flow cytometry to detect Annexin V-FITC and PI staining to determine the percentage of GBM cells undergoing apoptosis after exposure to DMSO or 10 lM 24OHC in
the presence or absence of 0.5 lg/ml cholesterol for 72 h. Data are shown as the mean  SEM (n = 3). LN229: **P = 0.0021, **P = 0.0046; GBM#P3: **P = 0.0012,
*P = 0.0193. Statistical significance was determined by one-way ANOVA.
E Western blot analysis of c-PARP in GBM cells treated with DMSO or 10 lM 24OHC in the presence or absence of 0.5 lg/ml cholesterol for 72 h.
F Tumorsphere formation assays for GBM#P3 and GBM#BG7 treated with DMSO or 10 lM 24OHC in the presence or absence of 0.5 lg/ml cholesterol. Scale
bar = 100 lm. Data are shown as the mean  SEM (n = 3). GBM#P3: **P = 0.0032, *P = 0.031; GBM#BG7: ***P = 0.0008, *P = 0.0242. Statistical significance was
determined by one-way ANOVA.
G CCK-8 assay to determine relative cell survival in LN229 or GBM#P3 cells after treatment with vehicle control or different concentrations of MbCD for 72 h. Data are
shown as the mean  SEM (n = 3). LN229: **P = 0.0051, ***P = 0.0002; GBM#P3: **P = 0.0018, ***P < 0.0001. Statistical significance was determined by one-way
ANOVA.
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Appendix Fig S10D). Finally, filipin staining confirmed that choles-
terol levels in GBM cells decreased under fatostatin treatment
(Fig 5K).
These results show that inhibition of cholesterol leading to
reduced cell growth by 24OHC is partly mediated by up-regulation
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Efavirenz inhibits GBM growth and prolongs survival of
intracranial tumour-bearing mice
Based on the findings that CYP46A1 inhibits GBM growth by
converting cholesterol to 24OHC, we investigated the effect of
efavirenz (EFV) (Fig 6A), which is an anti-HIV medication known
to activate CYP46A1 activity through binding to the enzyme’s allos-
teric site (Mast et al, 2014, 2017a; Anderson et al, 2016). Bioinfor-
matic chemical–protein interaction network analysis (STITCH)
indicated a strong association between EFV and CYP46A1 protein,
as well as PCNA (Appendix Fig S8A). EFV treatment reduced intra-
cellular levels of cholesterol in GBM cells (Fig 6B and C). The IC50
values for EFV were 16.81 lM in LN229 and 24.58 lM in GBM#P3
(Fig 6D). Also, increased levels of 24OHC were observed in culture
media from EFV-treated cells (P < 0.05, Fig 6E).
Functional studies showed that EFV potently reduced LN229 and
GBM#P3 tumour growth in a time- and dose-dependent manner
(Appendix Fig S8B–D). Colony formation assays confirmed the toxi-
city of EFV in LN229 and LN18 (P < 0.01; Fig 6F). Flow cytometry
analysis demonstrated that EFV induced apoptosis in GBM cells
(P < 0.001, Fig 6G), while sparing normal brain organoids and
NHAs (Appendix Fig S9A–C). In GSCs (GBM#P3, GBM#BG7 and
GBM#BG5), EFV significantly suppressed tumorsphere formation
(Fig 6H). At the molecular level, EFV led to increased levels of the
LXR target ABCA1 and the apoptosis marker cleaved PARP, but to
decreased levels of SREBP1 and LDLR, as well as PCNA and SOX2
(Fig 6I). Finally, exogenous cholesterol treatment (Appendix Fig
S9D) or CYP46A1 knockdown (Appendix Fig S9E and F) partially
restored EFV-induced growth inhibition of GBM cells. These results
suggest that the anti-cancer effect of EFV is mediated through regu-
lation of cholesterol levels.
The penetration of the blood–brain barrier (BBB) by EFV has
been well-documented in several studies. Median levels of EFV
concentration in the cerebrospinal fluid (CSF) were reported to be
11.1–30 lg/l (Tashima et al, 1999; Best et al, 2011; Tovar-y-Romo
et al, 2012; Yilmaz et al, 2012; Calcagno et al, 2015; Winston et al,
2015). EFV (0.09 mg/kg/day) by oral gavage treatment in C57BL/6J
mice, which is 6,667-fold lower than the dose given to HIV patients
(600 mg/kg/day), was recently reported to be sufficient to activate
CYP46A1 and to generate a 42% increase in 24OHC in mouse brain
tissue (Mast et al, 2014). Therefore, we investigated the therapeutic
impact of EFV in mice bearing LN229 and GBM#P3 orthotopic xeno-
grafts (Fig 6J). Oral administration of EFV (0.1 mg/kg/day) was
given to mice bearing tumours (n = 5 per group). Overall survival
of mice was prolonged (median survival: 29 versus 35 days for
GBM#P3; 27 versus 44 days for LN229; Fig 6K). For GBM#P3, biolu-
minescence imaging revealed a significant inhibition of tumour
growth at day 21 (P < 0.01, Fig 6L and M). A trend for increasing
body weight was also observed in EFV-treated animals (Fig 6N). No
cytotoxic effect of EFV was observed during treatment. IHC staining
of brain sections from tumour-bearing mice also demonstrated that
EFV suppressed the expression of PCNA and induced protein levels
of cleaved caspase-3 (Appendix Fig S10A–D). In conclusion, these
findings demonstrate that EFV represents a promising drug repur-
posing strategy for GBM treatment.
Discussion
Despite varying genetic backgrounds, several solid tumours includ-
ing GBM rely on lipid metabolism to fuel tumour growth (Cheng
et al, 2018). In the present study, GSEA of genomic data revealed an
accumulation of cholesterol in GBMs compared with normal brain
tissue. Consistent with previous reports (Guo et al, 2011; Geng et al,
2016), we showed that GBM cells require extracellular cholesterol to
fuel tumour growth, indicating that a metabolic reprogramming and
cholesterol homeostasis dysfunction occurs in GBM. Using a bioin-
formatic approach based on publicly available genomic data, we
identified the most dysregulated cholesterol-related gene, CYP46A1,
and investigated its role in GBM. The expression of CYP46A1 was
negatively correlated with WHO grade and malignant clinicopatho-
logical features of gliomas. Moreover, through large-scale survival
analysis, we showed that low CYP46A1 expression in glioma tissues
is associated with poor prognosis and can therefore serve as an
independent prognostic indicator.
Human CYP46A1, which is located on chromosome 14q32,
contains 15 exons and encodes for cholesterol 24-hydroxylase (Lund
et al, 1999). CYP46A1 is specifically expressed in the brain and is
◀ Figure 5. The downstream mechanisms of 24OHC in GBM progression.A Heatmap of differentially expressed transcripts in RNA-seq data from GBM#P3 cells treated with DMSO or 20 lM 24OHC for 72 h. Gene expression data were
mean z-transformed for display and coloured red for high expression and blue for low expression.
B, C GO and KEGG enrichment analysis of differentially expressed genes based on RNA-seq data with adjusted P-value.
D GSEA plot showing normalized enrichment scores (NESs) for cholesterol homeostasis, positive regulation of cholesterol efflux, SREBP targets and stem cell
proliferation signatures using RNA-seq data from 24OHC and DMSO-treated cells.
E Volcano plot highlighting up-regulated (red) and down-regulated (blue) genes based on RNA-seq data from GBM#P3 cells after 24OHC treatment. LXR targets,
SREBP targets and stemness transcription factors are specifically included. **adjusted P < 0.01, ***adjusted P < 0.001.
F qRT–PCR analysis of 24OHC-regulated genes in GBM#P3 cells after treatment with 20 lM 24OHC for 72 h. GAPDH was used as an internal control. Data are shown
as the mean  SEM (n = 3). ***P < 0.0001, ***P < 0.0001, *P = 0.0192, ***P = 0.0004, *P = 0.0118, *P = 0.0101, ***P < 0.0001. Statistical significance was
determined by two-sided Student’s t-test.
G Cell viability assay performed on GBM#P3 cells after 3 days of treatment with DMSO or 5–10 lM LXR-623 in the presence or absence of 10 lM 24OHC. Data are
shown as the mean  SEM (n = 3). *P = 0.031, *P = 0.050. Statistical significance was determined by one-way ANOVA.
H Western blot analysis of cholesterol metabolism-related proteins in LN229 or GBM#P3 after treatment with 24OHC (0–20 lM).
I Growth curves for LN229 cells transfected with control vector or SREBP1 plasmid and treated with 24OHC (0-40 lM) as assessed by a trypan blue test. Data are
shown as the mean  SEM (n = 3). **P = 0.0039. Statistical significance was determined by two-sided Student’s t-test.
J Colony-forming ability of GBM cell lines treated with DMSO or 20 lM fatostatin for 14 days. Data are shown as the mean  SEM (n = 3). ***P < 0.0001. Statistical
significance was determined by two-sided Student’s t-test.
K Representative images of filipin staining in LN229 (up) or LN18 (down) cells treated with different concentration of fatostatin (0–20 lM). Scale bar = 30 lm.
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responsible for the conversion of cholesterol into 24 (S)-hydroxy-
cholesterol (24OHC), which crosses the BBB into the systemic circu-
lation for metabolism (Lutjohann et al, 1996; Bjorkhem et al, 1997,
1998). The enzyme is responsible for at least 40–50% of brain
cholesterol turnover (Lutjohann et al, 1996; Xie et al, 2003). Dysreg-
ulation of CYP46A1 expression has been shown to occur in several
neurodegenerative diseases, including Parkinson’s, Alzheimer’s and
Huntington diseases (Bjorkhem et al, 2013; Leoni et al, 2013;
Soncini et al, 2016; Swan et al, 2016). However, its role in cancer
progression is less understood (Soncini et al, 2016). In GBM, abnor-
mal histone modifications such as acetylation and methylation are
closely related to tumorigenesis and drug resistance (Romani et al,
2018). In the present study, we found lower levels of histone modifi-
cation of H3K4me3 and H3K27ac sites at the promoter region of
CYP46A1, which may partially account for the decreased expression
of CYP46A1 in GBM relative to normal brain. In addition, it has
been reported that both the demethylating agent 50-aza-20-deoxycyti-
dine (DAC) and the histone deacetylase inhibitor (HDACi) tricho-
statin A (TSA) can induce CYP46A1 mRNA levels (Milagre et al,
2010; Nunes et al, 2010). Further studies of the upstream regulation
of CYP46A1 are therefore warranted.
In functional assays, we observed that overexpression of
CYP46A1 repressed GBM proliferation both in vitro and in vivo.
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through its enzyme activity. Further experiments indicated that
24OHC inhibits the growth of GBM through depletion of intracellu-
lar cholesterol. Therefore, the CYP46A1/24OHC axis suppresses
proliferation of GBM by disturbing cholesterol homeostasis. Previ-
ous studies have identified 24OHC as an activator of LXR and
inducer of several genes involved in cellular cholesterol efflux
(Lehmann et al, 1997; Janowski et al, 1999), such as the ATP-
binding cassette transporter A1 (ABCA1) in both neurons and glia
(Fukumoto et al, 2002) and apoE in astrocytes (Liang et al, 2004).
RNA-seq revealed that 24OHC caused an up-regulation of LXR
targets, such as ABCA1, ABCG1 and IDOL (the E3 ligase of LDLR),
and down-regulation of several SREBP target genes. In summary,
these data show that 24OHC acts, at least partially, by regulating the
activity of two essential transcription factors, LXR and SREBP,
involved in cholesterol homeostasis. Although 24OHC likely modu-
lates cell death also through other pathways (Noguchi et al, 2015),
our results show that inhibition of CYP46A1/24OHC is a critical
underlying regulator of cholesterol homeostasis in GBM. Thus,
restoration of the CYP46A1/24OHC axis is a promising GBM treat-
ment strategy.
Structure analysis of CYP46A1 suggested that distinct compounds
can bind the active site of the enzyme (Mast et al, 2008). EFV, a
BBB penetrating drug that has been used for the treatment of HIV,
was found to bind to the CYP46A1 allosteric site. The drug alters the
shape of the active site of cholesterol-free CYP46A1, making choles-
terol-binding tighter and enzyme catalysis more efficient (Mast et al,
2014). Supporting its CNS activity, oral administration has been
shown to improve long-term spatial memory, decrease amyloid-b
content and also prolong survival of Alzheimer’s mice (Mast et al,
2014, 2017b; Petrov et al, 2019). More recently, EFV has been
shown to reduce phosphorylated Tau (pTau) accumulation in a
human iPSC-derived AD model (van der Kant et al, 2019). EFV has
been reported to exert anti-tumour effects in some cancer types,
including renal clear-cell carcinoma, prostate cancer and ovarian
cancer (Landriscina et al, 2008; Houede et al, 2014; Perna et al,
2017). However, the efficacy of EFV in the treatment of GBM
remains unknown. In the current study, we observed that EFV (20
uM) significantly suppressed GBM growth and induced tumour cell
death. At the molecular level, EFV stimulated the activity of
CYP46A1, which resulted in elevated levels of 24OHC leading to a
◀ Figure 6. Efavirenz, an activator of CYP46A1, attenuates the growth of GBM cells and prolongs survival of mice bearing intracranial tumours.A The molecular structure of EFV.
B Intracellular concentrations of cholesterol in GBM cells after treatment with 20 lM EFV or DMSO and normalized to total protein. Data are shown as the
mean  SEM (n = 3). LN229: *P = 0.013; GBM#P3: **P = 0.0023. Statistical significance was determined by two-sided Student’s t-test.
C Filipin staining of GBM cells after treatment with EFV (0–20 lM). Scale bar = 30 lm.
D IC50 curves for EFV in GBM cells determined using OD readings (450 nm) from the CCK-8 assay. Data are shown as mean  SEM (n = 3).
E 24OHC levels in spent media from LN229 (left) or GBM#P3 (right) cells treated with DMSO or 20 lM EFV for 72 h quantified using targeted LC-MS/MS. Data are
shown as the mean  SEM (n = 3).
F Images and quantification of colonies formed by GBM cell lines after treatment with different concentrations of EFV (0–20 lM). Data are shown as the
mean  SEM (n = 3). LN229: **P = 0.0056, ***P < 0.0001; LN18: ***P < 0.0001. Statistical significance was determined by one-way ANOVA.
G Flow cytometry to detect Annexin V-FITC and PI staining to determine the percentage of GBM cells undergoing apoptosis after treatment with EFV (0–20 lM) for
72 h. Data are shown as the mean  SEM (n = 3). LN229: ***P = 0.0006, ***P < 0.0001; GBM#P3: ***P < 0.0001. Statistical significance was determined by one-
way ANOVA.
H Tumorsphere formation assays for GSCs treated with different concentrations of EFV (0–20 lM). Scale bar = 100 lm. Graphic representation of the quantification
of tumorsphere formation (right). Data are shown as the mean  SEM (n = 3). GBM#P3: **P = 0.0011, ***P = 0.0003, *** P < 0.0001; GBM#BG7: ***P < 0.0001;
GBM#BG5: **P = 0.0037, **P = 0.0015, ***P = 0.0002. Statistical significance was determined by one-way ANOVA.
I Western blot analysis of cholesterol homeostasis-related proteins (LDLR, ABCA1, P-SREBP1 and N-SREBP1), c-PARP, PCNA and SOX2 in GBM cells treated with EFV
(0–20 lM) for 72 h.
J Schematic diagram of the schedule for implantation and drug treatment in the GBM xenograft model. Seven days after implantation of tumour cells, mice were
treated with EFV by gavage (0.1 mg/kg/day). Bioluminescent imaging (BLI) using IVIS was performed at days 4, 7, 14 and 21.
K The survival curves of tumour-bearing mice implanted with LN229 or GBM#P3 cells after EFV or PBS treatment (n = 5 per group). A log-rank test was used to
assess statistical significance.
L, M Bioluminescent images and the corresponding quantification of tumours in mice implanted with GBM#P3 cells at days 7 (n = 5 per group, P = 0.58) and 21 (n = 5
per group, P = 0.005). Data are shown as mean  SEM. Statistical significance was determined by two-sided Student’s t-test.
N Body weight of tumour-bearing mice after 3 weeks of EFV or PBS treatment. Data are shown as the mean  SEM (n = 5 per group). Statistical significance was
determined by two-sided Student’s t-test.
Figure 7. Schematic representation of CYP46A1 contribution in GBM
progression.
(Left panel) GBM cells have an excessive cholesterol accumulation caused by
CYP46A1 down-regulation, which leads to a reduced 24OHC production that in
turn cause a suppression of LXR signalling and an induction of SREBP targets.
(Right panel) Restoration of CYP46A1 activity by EFV impairs GBM tumorigenic
properties by increasing 24OHC levels, which in turns decreases intracellular
cholesterol levels. Mechanistically, EFV treatment leads to the up-regulation of
LXR target genes including ABCA1, and down-regulation of SREBP1 activity and
LDLR expression.
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decreased accumulation of cholesterol, accompanied by increased
levels of the LXR target ABCA1, and decreased levels of SREBP1 and
LDLR. Notably, exogenous cholesterol treatment or CYP46A1
knockdown partially restored growth inhibition of GBM cells
induced by EFV, suggesting that the anti-cancer effect of EFV is
mediated at least partially, by regulating cholesterol levels. EFV has
been frequently associated with neuropsychiatric adverse events
(NPAE) when given to HIV patients at high doses (Apostolova et al,
2017). However, major NPAE were not observed in mice at lower
doses of EFV, indicating an appropriate therapeutic window (Mast
et al, 2017b). Finally, EFV showed promising anti-glioma effects
both in vitro and in vivo. A schematic representation of our results
is illustrated in Fig 7.
We show that accumulation of cholesterol and dysregulated
cholesterol homeostasis in GBM is mediated by loss of CYP46A1
and that CYP46A1 represents a viable therapeutic target in GBMs.
An activator of CYP46A1 inhibited tumour growth in vitro and
in vivo by increasing the production of the cholesterol metabolite
24OHC, thus disturbing cholesterol homeostasis in GBM. Moreover,
restoration of the activity of the CYP46A1/24OHC signalling axis by
EFV, a medication currently in widespread use for the treatment of
AIDs, might be a promising GBM therapeutic strategy.
Materials and Methods
Cell culture
Patient-derived glioma stem cells (GSCs), GBM#P3, GBM#BG5 and
GBM#BG7, were established from GBM surgical specimens at the K.
G. Jebsen Brain Tumour Research Centre, Department of Biomedi-
cine, University of Bergen (Bergen, Norway). Cells derived from
primary tumours were validated as GSCs in neurosphere formation
assays and through the expression of GSC markers, such as SOX2
and OLIG2. Short tandem repeat (STR) profiling (Appendix Table S2)
was carried out to confirm GSC identity. The cells were cultured in
NeurobasalTM Medium (Gibco/Thermo Fisher Scientific; Waltham,
MA) supplemented with B27 supplement (Invitrogen; Carlsbad, CA),
20 ng/ml bFGF (PeproTech; Rocky Hill, NJ), 20 ng/ml EGF (Pepro-
Tech) and 5 lg/ml LDL (Millipore, LP2-2MG). Accutase (Thermo
Fisher Scientific; Waltham, MA) was used to digest tumorspheres for
expansion of GSCs. The serum-grown GBM cell lines (LN229, U251
and LN18) were purchased from the American Type Culture Collec-
tion (Manassas, VA) and cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Thermo Fisher Scientific) supplemented with 10%
foetal bovine serum (FBS; Clark, VA). Normal human astrocytes
(NHAs) were obtained from Lonza (Walkersville, MD) and cultured
in the provided astrocyte growth media supplemented with rhEGF,
insulin, ascorbic acid, GA-1000, L-glutamine and 5% FBS.
Ectopic expression
Lentivirus expressing CYP46A1 or a control sequence was obtained
from GeneChem (Shanghai, China). A lentivirus with luciferase was
obtained from Obio (Shanghai, China). Lentivirus expressing
CYP46A1 was used to infect LN229 and GBM#P3 followed by puro-
mycin selection (Sigma-Aldrich; St. Louis, MO) to generate cell lines
stably expressing CYP46A1. The ORF of SREBP1 in pEnter and
vector plasmid control were purchased from Vigene Biosciences
(Jinan, Shandong, China). Transient transfection was carried out
using Lipofectamine 3000 (Life Technologies; Gaithersburg, MD)
according to the manufacturer’s protocol.
RNA isolation and quantitative real-time PCR
Total RNA was extracted from cells using TRIzol reagent (Invitro-
gen; Carlsbad, CA, USA) and reverse-transcribed using the Rever
Tra Ace qPCR RT Kit (Toyobo; Osaka, Japan). cDNA was amplified
using SYBR Green on the Roche Light Cycler 480 for quantification.
The relative expression levels of mRNA were normalized to glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH). Sequences of the
primers used are shown in Appendix Table S3.
Clinical specimens
Archived paraffin-embedded glioma tissues (WHO grades II-IV)
were collected from patients (n = 58) who underwent surgery in the
Department of Neurosurgery, Qilu Hospital of Shandong University.
Normal brain tissue samples (n = 6) were taken from trauma
patients who underwent partial resection of normal brain as decom-
pression treatment for severe head injuries. The informed consent
was obtained from all subjects and that the experiments conformed
to the principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report.
Immunohistochemistry
Paraffin-embedded blocks containing tissue from traumatic brain
injury, glioma tissues or xenografts were sectioned (5 lm). Slides
were incubated with primary antibody, rabbit anti-CYP46A1
(ab198889, 1:100, Abcam; Burlingame, CA), rabbit anti-PCNA
(ab29, 1:10,000; Abcam) and rabbit anti-cleaved caspase-3 (ab2302,
1:200; Abcam). Detailed protocols have been described previously
in Supplementary Materials (Han et al, 2018). Staining was evalu-
ated independently by two experienced neuropathologists.
Western blotting
Cells were lysed with RIPA lysis buffer (Thermo Fisher Scientific;
Waltham, MA, USA) supplemented with a protease and phos-
phatase inhibitor cocktail (Sigma-Aldrich; St. Louis, MO, USA). The
BCA Protein Assay Kit (Beyotime, Shanghai, China) was used to
determine protein concentration according to the manufacturer’s
instructions. Equal amounts of protein extracts were separated by
SDS–PAGE followed by electrotransfer of protein onto PVDF
membrane (Merck Millipore; Billerica, MA, USA). The membrane
was blocked with skim milk and incubated with primary antibodies
followed by incubation with a horseradish peroxidase (HRP)-conju-
gated secondary antibody (ZSGB-BIO; Beijing, China) for 1 h.
Immunoreactivity was detected with ECL (Merck Millipore; Biller-
ica, MA, USA), and GAPDH was used as a loading control. The
following primary antibodies were used: rabbit anti-ABCA1
(ab7360, 1:500, Abcam), rabbit anti-LDLR (ab52818, 1:500, Abcam),
rabbit anti-CYP46A1 (ab198889, 1:200, Abcam), rabbit anti-PCNA
(ab92552, 1:5,000, Abcam), rabbit anti-cleaved caspase-3 (ab2302,
1:500, Abcam), rabbit anti-OLIG2 (ab109186, 1:2,000, Abcam),
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rabbit anti-GFAP (ab33922, 1:2,000, Abcam) and rabbit anti-SREBP1
(ab3259, 1:200, Abcam); rabbit anti-GAPDH (#5174, 1:1,000, Cell
Signaling Technology; Danvers, MA), rabbit anti-cleaved PARP
(#5625, 1:1,000, Cell Signaling Technology) and rabbit anti-SOX2
(#3579, 1:1,000, Cell Signaling Technology).
Cell survival and IC50 analysis
Cells were seeded in triplicate in 96-well culture plates at 3000 cells
per well. Cholesterol (HY-N0322, MedChemExpress; Monmouth
Junction, NJ) was dissolved in 40% methyl-b-cyclodextrin (MbCD,
HY-101461, MedChemExpress). Corresponding reagents such as
24OHC (HY-N2370, MedChemExpress) and efavirenz (EFV; HY-
10572, MedChemExpress) were added to cells in DMEM containing
1% FBS and 1% penicillin/streptomycin for established cell lines or
neurobasal medium for patient-derived GSCs. Cell viability assays
were performed using the trypan blue assay (15250061, Gibco/
Thermo Fisher Scientific) or the Cell Counting Kit-8 (CK04, Dojindo;
Rockville, MD) according to the manufacturer’s protocol. Raw OD
values at 450 nm were analysed using PRISM software for CCK-8.
For IC50 analysis, EFV or 24OHC concentrations were log10-trans-
formed, and values were normalized to per cent viability relative to
vehicle-treated cells.
For the IncuCyte proliferation assays, cells were treated with
DMSO, 24OHC or EFV at various concentrations. Cells were moni-
tored and imaged using an IncuCyte S3 Live-Cell Analysis System
(Essen BioScience, Ltd.; Welwyn Garden City, Hertfordshire, UK),
and data were analysed by IncuCyte Confluence version 1.5 soft-
ware (Essen Bioscience). All experiments were performed in tripli-
cate.
Establishment of intracranial GBM xenografts and
efavirenz treatment
Experimental procedures were approved by the Research Ethics
Committee of Shandong University and the Ethics Committee of Qilu
Hospital (Shandong, China). The Institutional Animal Care and Use
Committee (IACUC) of Shandong University approved all animal
procedures. Four-week-old male athymic nude mice (Foxn1nu mut/
mut; SLAC Laboratory Animal Center; Shanghai, China) were bred
under specific pathogen-free conditions at 24°C on a 12-h day–night
cycle. For orthotopic transplantation, mice were grouped randomly
(n = 5 per group) and intracranially injected with 1 × 106 LN229 or
GBM#P3 cells resuspended in 10 ll PBS. At day 7 after cell implan-
tation, mice were given drugs (efavirenz) or PBS by oral gavage at
0.1 mg/kg/day until sacrifice based on tumour burden defined by
the observation endpoints of the experiments (neurological signs
became apparent). GBM#P3 expressing luciferase xenograft growth
was monitored with bioluminescent imaging using an In Vivo Imag-
ing System (IVIS) Spectrum (Perkin-Elmer; Waltham, MA). Brains
were collected and fixed in 4% formaldehyde for haematoxylin and
eosin (HE) staining and IHC analysis.
LC-MS analysis
24OHC measurements were performed by Biotree Biotechnology
Co., Ltd (Shanghai, China). Cell samples were prepared as
follows: 1,000 ll of extract solvent (precooled at 20°C,
acetonitrile–methanol–water, 2:2:1) was added to pelleted cells, and
samples were vortexed for 30 s and homogenized at 45 Hz for
4 min. Media samples were prepared as follows: a 200 ll aliquot of
each individual sample was precisely transferred to an Eppendorf
tube. Methanol (400 ll) and acetonitrile (400 ll) were added to the
aliquot, and the samples were vortexed for 30 s. Cell samples or
media were sonicated for 15 min in an ice-water bath followed by
incubation at 20°C for 1 h and centrifugation at 13,523 g at 4°C
for 15 min. A 750 ll aliquot of the clear supernatant was transferred
to a new Eppendorf tube and dried under a gentle nitrogen flow.
The residual was reconstituted with 150 ll of solution (acetonitrile–
methanol–water, 2:2:1), centrifuged at 13,523 g at 4°C for 15 min.
An 80 ll aliquot of the clear supernatant was transferred to an auto-
sampler vial for UHPLC-MS/MS analysis. Stock solutions were indi-
vidually prepared by dissolving or diluting each standard substance
to give a final concentration of 10 mmol/L. The UHPLC separation
was carried out using an Agilent 1290 Infinity II Series UHPLC
System (Agilent Technologies; Santa Clara, CA), equipped with an
Agilent ZORBAX SB-C18 (50 × 2.1 mm, 1.8 lm, Agilent Technolo-
gies). Calibration solutions were subjected to UHPLC-MRM-MS/MS
analysis using the methods described above. The calibration stan-
dard solution was diluted stepwise, with a dilution factor of 2.
These standard solutions were subjected to UHPLC-MRM-MS anal-
ysis. The signal-to-noise ratios (S/N) were used to determine the
lower limits of detection (LLODs) and lower limits of quantitation
(LLOQs). The LLODs and LLOQs were defined as the analyte
concentrations that led to peaks with signal-to-noise ratios (S/N)
of 3 and 10, respectively, according to the US FDA guideline for
bioanalytical method validation. The precision of the quantitation
was measured as the relative standard deviation (RSD),
determined by injecting analytical replicates of a QC sample. The
accuracy of quantitation was measured as the analytical recovery
of the QC sample determined. The per cent recovery was
calculated as [(mean observed concentration)/(spiked concentra-
tion)] × 100%. Finally, 24OHC content for each sample was quan-
tified and normalized to whole-cell protein or cell count. Values
shown were normalized to controls.
Cholesterol measurements
Cholesterol content was measured using the Cholesterol Quantita-
tion Kit (Sigma-Aldrich, MAK043-1KT), and filipin staining was
performed according to the manufacturer’s protocols. For filipin
staining (free cholesterol marker), GBM cells were treated for 72 h
with 24OHC, EFV (MedChem) or vehicle control. Cells were stained
with 0.5 mg/ml filipin in 1% BSA/PBS for 1 h after fixation with
4% paraformaldehyde for 15 min and rinsed 3 × 5 min with PBS.
Images were captured by confocal microscopy (Leica TCS SP8;
Wetzlar, Germany).
RNA sequencing
GBM#P3 cells were treated with 20 lM 24OHC or DMSO for 72 h.
Cells were harvested, and total RNA was isolated using TRIzol
(Invitrogen). RNA sequencing (RNA-seq) was carried out by OE
Biotech. Co., Ltd. (Qingdao, Shandong, China). The genome-wide
transcriptomic analysis was performed on a set of 3 separate experi-
ments (24OHC and vehicle control treatment groups). P-values were
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adjusted using Benjamini and Hochberg’s multiple test correction
procedures. Differential expression was determined based on fold
change (FC) and FDR with |log2(FC)| > 1 and FDR < 0.01. DAVID
(https://david.ncifcrf.gov/) was used to perform GO and KEGG
analysis, and data visualization was accomplished using R software.
Gene set enrichment analysis (GSEA; https://www.broadinstitute.
org/gsea/index.jsp) was performed to find differential phenotypes
between 24OHC and vehicle control treatment groups.
Chromatin immunoprecipitation (ChIP) assays
The EZ-ChIP Immunoprecipitation Kit (Millipore; Billerica, MA,
USA) was used to perform ChIP assays. The following antibodies
were used: anti-H3K27ac (ab4729, 1:100, Abcam), anti-H3K4me3
(ab8580, 1:100, Abcam) and normal rabbit IgG (#2729, 1:100, Cell
Signaling Technology). The sequences of the primers for H3K27ac
and H3K4me3 binding sites at the CYP46A1 promoter were the
following: F 50-GTGGTCCACGTGGTACTTCT-30 and R 50-CATCCAC
GACATCTCGCACA-30. Briefly, GBM cells or NHAs were cross-linked
with 1% formaldehyde solution for 10 min and quenched with
0.125 M glycine. Cells were spun down, washed, resuspended, lysed
and ultra-sonicated. Fragmented chromatin extract was precleared
with agarose beads from the ChIP Kit and incubated overnight with
antibodies or normal rabbit IgG as the control. After washing, elution
and reverse cross-linking, DNA was analysed by qPCR.
Flow cytometry
Cells were harvested, rinsed twice with PBS, fixed with 75% (v/v)
ethanol overnight at 4°C and stained with propidium iodide (PI; BD
Biosciences; San Jose, CA, USA) at room temperature for 20 min.
To detect apoptosis, cells were rinsed with PBS, resuspended in
200 ll binding buffer and incubated with Annexin V-FITC and PI
(BD Biosciences; San Jose, CA, USA) at room temperature for
15 min. Both cell cycle distribution and apoptosis were analysed on
a C6 flow cytometer (BD Biosciences; San Jose, CA, USA). Data
were postprocessed using NovoExpress Software (ACEA Bios-
ciences; San Diego, California, USA).
Caspase-3/7 activity assay
In vitro caspase-3/7 activity was determined using CellEventTM
Caspase-3/7 Green Detection Reagent (Invitrogen; Carlsbad, CA,
USA) according to the manufacturer’s protocol. For the kinetic
assay, LN229 cells were treated with 24OHC at different concentra-
tions (0–20 lM) and 2 lM Caspase-3/7 Green Detection Reagent.
IncuCyte S3 Live-Cell Analysis System (Essen BioScience, Ltd.;
Welwyn Garden City, Hertfordshire, UK) was used to visualize the
progression of apoptosis using FITC/Alexa FluorTM 488 filter settings
at desired time points. Cells were monitored and imaged with the
IncuCyte S3 Live-Cell Analysis System (Essen BioScience, Ltd.;
Welwyn Garden City, Hertfordshire, UK), and graphics were gener-
ated with IncuCyte software.
Tumorsphere formation assay
GSCs (1,000 cells/ml/well) were seeded in 6-well ultra-low adhe-
sion plates (Corning Inc.; Corning, NY, USA) or general plates
(Corning Inc.) and cultured for 10 days. Inverted phase-contrast
microscopy (Nikon; Tokyo, Japan) was used to count and acquire
images of the non-adherent tumorspheres.
Colony formation assay
LN18 or LN229 (1,000 cells/well) cells were seeded in 6-well culture
plates in triplicate and incubated at 37°C in a humidified chamber of
5% CO2 for 14 days. Colonies were washed with PBS, fixed in
methanol for 15 min and stained with crystal violet for 15 min at
room temperature. Images of colonies were acquired under bright-
field microscopy (Nikon; Tokyo, Japan), and those with a diameter
of ≥ 100 lm were counted.
Live–dead cell staining
Live–dead cell staining was performed using the Live/Dead Cell
Double Staining Kit (Sigma-Aldrich; St. Louis, MO, USA) according
to manufacturer’s protocol. Briefly, brain organoids were treated
with DMSO or efavirenz for 3 days. The medium was changed
before live–dead cell staining to exclude the influence of DMSO and
efavirenz on staining. Calcein-AM and PI working solutions were
prepared in PBS at a proper dilution. The staining solutions were
mixed into a working solution with the brain organoid suspension
at a ratio of 1:2 (v/v) and incubated at 37°C for 15 min. Images for
live–dead cells were captured with confocal microscopy (Leica TCS
SP8; Leica Microsystems; Wetzlar, Germany).
Brain organoid cultures
The preparation and culture of brain organoids have been described
previously (Bjerkvig et al, 1986). Briefly, rat foetal brains at the 18th
day of gestation were dissected out aseptically, cut into
0.5 × 0.5 mm pieces and rinsed three times with PBS. Single cells
were obtained through serial trypsinization and seeded into agar-
coated multi-well dishes for 21 days to form mature brain orga-
noids. Images were captured, after treatment of brain organoids
with 24OHC, EFV or DMSO (vehicle control) for 3 days, using
bright-field microscopy (Nikon; Tokyo, Japan).
Immunofluorescence
GBM#P3 tumorspheres were seeded on poly-D-lysine (Sigma-
Aldrich)-coated coverslips. Cells were fixed in 4% paraformalde-
hyde in PBS and blocked with 10% goat serum (Beyotime,
Shanghai, China) and 0.3% Triton X-100 in PBS for 30 min.
Slides were incubated with mouse monoclonal SOX2 antibody
(sc-365823, 1:100, Santa Cruz Biotechnology; Dallas, TX) over-
night and incubated with anti-mouse IgG-conjugated Alexa Fluor
568 (A-11031, 1:500, Invitrogen) for 2 h at room temperature.
Nuclei were counterstained with DAPI (C1005, Beyotime;
Haimen, Jiangsu, China). Images were captured with a Leica
inverted microscope.
Statistical analysis
Kaplan–Meier survival curves were generated and compared using
the log-rank test. The association between CYP46A1 expression and
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clinicopathological characteristics was determined in a two-tailed
chi-square test. For animal studies, mice were randomly allocated to
control or treated group. No blinding was done. The Kolmogorov–
Smirnov test was used to assess the normal distribution of data.
Statistical analysis was performed using an unpaired Student’s t-test
for two-group comparison and one-way analysis of variance
(ANOVA) for multi-group comparisons using GraphPad Prism 7.0
(La Jolla, CA). All the experiments were repeated at least three times
with triplicates unless stated otherwise. Data for each treatment
group were represented as the mean  SEM. All tests were
two-sided, and P-values < 0.05 were considered to be statistically
significant.
Data availability
The datasets in this study are available in the following databases:
The RNA-seq data: Gene Expression Omnibus (GEO) with the
record numbers GSE54047 (https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE54047), GSE46016 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE46016) and GSE46014 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46014).
Expanded View for this article is available online.
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